You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 51 No. 10, October 1994 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Anti—Myelin Basic Protein and Anti—Proteolipid Protein Antibody-Secreting Cells in the Cerebrospinal Fluid of Patients With Acute Optic Neuritis

Finn T. Sellebjerg, MD; Jette L. Frederiksen, MD; Tomas Olsson, MD, PhD

Arch Neurol. 1994;51(10):1032-1036.


Abstract

Objective
To study the intrathecal synthesis of antimyelin basic protein (MBP) and anti-proteolipid protein (PLP) antibodies in patients in the early stages of multiple sclerosis.

Design and Setting
A study of consecutive patients with acute optic neuritis (ON) who were undergoing lumbar punctures in an ambulatory unit.

Patients
Eleven patients with acute idiopathic ON and 14 patients with acute ON as a symptom of definite multiple sclerosis (the diagnosis of which was supported by clinical or laboratory findings). Nineteen patients with other neurological diseases (10 with inflammatory diseases) served as controls.

Main Outcome Measures
Numbers of anti-MBP and anti-PLP antibody-secreting cells in peripheral blood and cerebrospinal fluid samples that were enumerated with an immunospot assay.

Results
Cerebrospinal fluid cells that secreted anti-MBP or anti-PLP antibodies were detected in 10 of 15 and in 21 of 23 patients with acute ON, while they were detected in nine of 18 and in six of 18 patients with other neurological diseases, respectively. Patients with ON had significantly more anti-PLP-secreting cells than did patients with other neurological diseases (P<.01). No difference was observed for anti—MBPsecreting cells. A significant correlation between the time from onset and the number of anti—PLP-secreting cells was found in patients with idiopathic ON (P<.02).

Conclusions
These data suggest that anti-PLP antibodies are a more specific finding in demyelinating disease than anti-MBP antibodies. Furthermore, they suggest that anti—PLP antibodies may arise as a consequence of the demyelinating process.



Author Affiliations

From the Department of Neurology, Golstrup Hospital, University of Copenhagen, Golstrup, Denmark (Drs Sellebjerg and Frederiksen), and the Department of Neurology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden (Dr Olsson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis
Sellebjerg et al.
Mult Scler 1998;4:127-131.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.